. Corynebacterium parvum is Reagents Ltd, Beckenham, Kent. an adjuvant in non-tumour s stems Tumours. Tumours appeared in male an adjuvant in non-tumour systems CBAT6T6 mice 4-5 months after the intra-(reviewed by Howard, Scott and Christie, muscular injection in the thigh of 0.1 ml of 1973) and there is evidence that it can, methylcholanthrene (5 mg/ml in olive oil, when used in combination with irradiated kindly provided by Dr J. A. Wright of the tumour cells, potentiate the immune Imperial Cancer Research Fund, London), response to tumour-specific transplan-and were maintained by transplantation in tation antigens (TSTA) (Proctor, Rudenmale CBAT6T6 mice and in tissue culture. stam and Alexander, 1973; Scott, 1974a) . Three independently induced tumours, This paper describes the use of '. parvum M2, M3 and M4, were used in these experi-This paper describes the use Of C. parvu ''1ments. and irradiated tumour cells for the Tum.our cell suspensions-Cells were immunotherapy of methyleholanthrene inobtained directly from tumours by mincing duced fibrosarcomata (MC fibrosarcomata) small fragments of non-necrotic tumour of CBA mice. Some factors controlling tissue in PBS, pushing the fragments through the success of therapy are analysed. a sieve, allowing the debris to settle and washing the cells in PBS. Viability was tumour growth by the highest dose of 20-30% by trypan blue exclusion. C. parvum (350 ,tg cultured M4 cells and treated 2 days later Foetal calf suspensions.-10-14 day old with graded doses of irradiated M4 cells foetuses were minced, the fragments stirred and C. parvum. Table II shows that in 0.1% trypsin in PBS for 5-10 mm at 370C, dilutions of C. parvum or of irradiated the fluid decanted, calf serum added to 10% tumour cells given alone did not suppress and spun at 1000 g for 5 mm. The cell pellet . . r was resuspended in PBS-10% FCS. Viability or significantly retard tumour growth. was >90%.
Mixtures containing the smallest number Irradiation of cells.-Cells were exposed (5X103) of M4 cells were ineffective but to 10,000 rad from a 60Co source.
with 5 x 104 M4 cells therapy was successful Tumour challenge and therapy.-0-1 ml at the lower doses of C. parvum (1.4 and (for dorsal s.c. challenge) or 0-2 ml (for i.v. 5.5 Itg) but not at the higher doses challenge) of tumour derived cells in PBS or (22 and 88 ,ug), although with 22 ,tg of tissue culture cells in medium were injected. C. parvum there was a significant reduction For therapy, 0-05 ml of dilutions of C. parvum of tumour weight (the only one in this and/or tumour cells in saline were injected experiment). When the number of M4 into both footpads. ce raiedto When th erapy Mice challenged s.c. were palpated weekly cells was raisedto 5 x 105, complete therapy for tumours until control tumours started to was achieved with 22 ,ug of C. parvum, ulcerate and were then killed and the tumours and partial therapy (only 1/5 mice with weighed. Mice challenged i.v. were scored tumours) at the other dilutions. The for survival up to 80 days, the remaining mice mice which remained tumour-free at then being killed. Lungs were examined for 6 weeks had not developed palpable tumours by the method of Wexler (1966) .
tumours earlier. T cell depleted mice.-Mice were thymecto-Since in this experiment tissue culture mized, irradiated (850 rad) and reconstituted M4 cells were used both for tumour chalwith 2 > 106 bone marrow cells followino' the method of Davies et al. (1966) . lenge and therapy, the possibility that Statistics.-Statistical manipulation of the tumour suppression could be due to data was carried out by Mr D. Field, Well-immunity to tissue culture constituents come Research Laboratories. The logl0 geowas excluded by repeating part of the metric means of tumour weights were comexperiment, using 106 irradiated tumour pared using a pooled variance estimate from derived M4 cells for therapy. Five/5 mice all groups. The arithmetic means of survival developed tumours in the untreated contimes were compared by Student's t test. trols, and in the groups given M4 cells or Significancẽ~~~t rls ans P<0 the grusgvn clso Significance was P<0-05.
C. parvum dilutions alone. Therapy with mixtures, as before, was successful only with lower doses of C. parvum: 350 ,ug, RESULTS 5/5; 88 /ag, 4/5; 22 jug, 1/5; 5.5 jag, 0/5.
Effect of C. parvum injected alone i.v. against tumour challenge
Efficacy of delayed therapy Mice were injected i.v. with 2 x 105, Mice were injected s.c. with 104 tissue or s.c. with 104 tissue culture M4 cells, and culture M4 cells 6 or 10 days before treat-2 days later injected i.v. with dilutions of ment with 5 x 105 irradiated tissue culture C. parvum. Table I shows that the only M4 cells, 22 jag C. parvum, or mixtures. significant effect was a retardation of s.c. Table III shows that therapy was successful at 6 days after tumour challenge, when The effect of T cell depletion no convincingly palpable tumours could Mice depleted ofT cells by thymectomy, be found. In the first experiment one irradiation and reconstitution with bone tumour was palpable at 14 days after s.c. marrow cells (TX-IRR-BM) and irradiated challenge, but not at Day 21; in the second reconstituted controls (IRR-BM) were experiment all 5 tumours were palpable challenged s.c. with 104 M4 cells and at Day 14, and 4 out of 5 had disappeared treated 2 days later with 5 x 105 at Day 21.
irradiated tissue culture M4 cells, 5*5 Therapy 10 days after s.c. challenge, ,ug C. parvum or a mixture (Table IV) . when the tumours were already palpable, Therapy was impaired in T cell depleted was ineffective.
mice. Notdone Specificity of therapy M4 or M2 cells and 2 days later injected Mice were injected s.c. with 1-5 x 104 in the footpads with 120 ,tg of C. parvum M4 cells or 2 x 104 M3 cells and 2 days and 106 living M2 or M4 cells. All the later received therapy with 5 x 105 mice treated with C. parvum and homoirradiated tissue culture M3 or M4 cells, logous tumour cells were without lung 22 /tg C. parvum or mixtures (Table V) . nodules when killed 80 days after i.v.
Homologous cells were required in therapy challenge. Treatment with mixtures mixtures.
containing heterologous cells did not pro-The specificity of therapy was con-long survival (M4 cell challenge, mean firmed using i.v. challenge with tumour survival time, days i s.e., untreated cells. Mice were injected i.v. with 2 x 105 controls 49 0 j 3-6, C. parvum-M2 cell treatment 54-9 ± 4-8; M2 cell challenge, not excessive C. parvum is required, untreated controls 35-2 ± 1 2, C. parvum-effective doses lying between 1-4 and 120 M4 cell treatment 38-6 = 1-5).
,tg, and increasing with the number of To increase the chances of detecting a tumour cells. These dose requirements low level of cross reactive anti-tumour are in contrast to those for therapy with resistance, further specificity experiments i.v. C. parvum alone where only the highest were performed using a protection model dose (350 ,tg) retarded tumour growth. in which treatment preceded tumour A similar distinction in dose requirements challenge.
has previously been described for the Mice were injected in the footpads P-185 mastocytoma growing on the footwith 106 irradiated tissue culture M3 or pad of C57B1 x DBA/2 mice, where M4 cells, with dilutions of C. parvum or retardation of tumour growth could be with mixtures, and were challenged s.c. best achieved with a high dose (700 ,tg) 7 days later with 4 x 104 viable tumour of C. parvum i.v. (Scott, 1974b) , whereas derived M3 or M4 cells. Table VI shows regressions after intralesional injections the results of the M4 challenge experiment. were more frequent with lower (35 or 70 Prior treatment with M4 cells alone con-,ug) than higher (350 ,ug) doses (Scott, ferred partial resistance, which became 1974a). It has been suggested that higher complete in conjunction with 22 ,ag of doses of C. parvum are ineffective for C. parvum. Heterologous M3 cells alone intralesional therapy because the draining or admixed with 22, 5-5 or 1-4 ,ug of C. nodes become too severely disorganized by parvum did not generate resistance.
histiocytic infiltration to mount an immune The reciprocal experiment using M3 response to tumour antigens (Scott, 1974c) . cells for s.c. challenge gave analogous However, the observation in this paper results; only M3-C. parvum mixtures were that the upper limit for the dose of C. protective (results not shown).
parvum in mixtures increases with the number of tumour cells suggests an The use of foetal cells explanation based on the necessity for a C. parvum-foetal cell mixtures were balance between C. parvum and tumour tested in the protection model. Up to antigen. 3 x 106 lining or irradiated syngeneic An intact T cell system was required (CBA) or allogeneic (BALB/c) 10-14 day for therapy. This, together with the foetal cells were injected in the footpads exquisite specificity of the system, with varying doses of C. parvum 7 days suggests that C. parvum is promoting before s.c. challenge with M3 or M4 trells. immunity to the non-cross-reacting TSTA. No suppression or retardation of tumour It remains to be determined whether cell growth was achieved. mediated or humoral immunity is involved, but cell mediated must be favoured since it DISCUSSION has already been shown for the P-185
The present results show that develmastocytoma in C57B1 x DBA/2 mice oping MC fibrosarcomata can be eliminated that lymph node cells, but not serum, after treatment with mixtures of C. parvum from mice pretreated with C. parvum and and irradiated or living tumour cells. irradiated tumour cells prevents the out-The following factors affected the outcome growth of admixed tumour cells transof treatment.
ferred to a sub-lethally irradiated recipient Sufficient tumour cells are required (Scott, 1975) . in the mixtures, the minimum for irradiated Although therapy given 6 days after cells lying between 5 x 103 and 5 x 104. tumour challenge suppressed tumour No upper limit was detected, as therapy growth, therapy at 10 days did not even was successful with the largest number retard tumour growth. This suggests there tested, 106 living cells. Sufficient but is a critical tumour size, beyond which therapy must fail, due either to the logarithmic growth ofthe tumour outstripping the constant destruction of tumour cells by the immune system or to blocking factors.
Therapy or protective immunity required the use of the same tumour cells for treatment and challenge; there was no evidence that C. parvum, as used in this study can potentiate immunity (of a type conferring transplantation resistance) to the cross-reacting foetal antigens known to exist on mouse and rat MC-fibrosarcomata (Braun, 1970; Baldwin, Glaves and Vose, 1972; Thomson and Alexander, 1973; LeMevel and Wells, 1973) .
The implications of the animal experimental work for the use of C. parvum as an immunotherapeutic agent in man have been reviewed by Scott (1974c) , but some comments specifically related to the present work can be made. If C. parvum is used with irradiated tumour cells for active specific immunotherapy, the number of tumour cells used may not be critical, although it would be justifiable to use the maximum feasible so as not to fall below the antigen threshold. Care must be taken to avoid using excessive C. parvum. In order to circumvent C. parvum overdose it would be preferable to apply repeated treatments to areas drained by different lymph nodes. If no tumour cells are available, active specific immunotherapy may still be attempted by injecting C. parvum on its own at a site where it will stimulate a draining lymph node which is likely to be already containing tumour antigen. It has been shown in the P815 mastocytoma system that C. parvum and irradiated tumour cells injected at different sites can generate protective immunity, provided that they stimulate the same lymph node (Scott, 1975) . In the light of the specificity data presented in this paper, it will be preferable to use irradiated autochthonous tumour cells whenever possible unless there is good evidence for cross-reacting antigens of a type capable of stimulating anti-tumour resistance.
Finally, although it has now been demonstrated in this system and for the P-815 mastocytoma (Scott, 1974a, b ) that i.v. treatment with C. parvum produces a relatively weak anti-tumour effect, this method of administering C. parvum should not be discounted for clinical use. Firstly, it might enable C. parvum to come into contact with, and stimulate the immune response to, systemically distributed tumour cells at sites such as the liver or bone marrow. Secondly, since i.v. C. parvum produces an anti-tumour effect which is independent of the immune response to TSTA (Scott, 1974c) , it might provide some resistance to tumour growth in situations where the possibility of active specific immunotherapy is diminished either by lack of antigenicity of the tumour or by immunological energy of the patient.
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